Analysis reports / SIC major group
Chemicals And Allied Products financial report
Mechanical ranking by stated metric from SEC/FRED data; not a recommendation, endorsement, or quality/investment judgment.
Chart
Percent metrics
USD metrics
Ratio metrics
Distribution Summary
| Metric | Count | Median | Minimum | Maximum | Min-Max range |
|---|---|---|---|---|---|
| Net margin | 213 | 1.14% | -148.38% | 98.54% | 246.92% |
| Operating margin | 195 | 2.64% | -149.34% | 65.58% | 214.92% |
| Revenue growth | 245 | 8.05% | -92.83% | 230194.59% | 230287.43% |
| Free cash flow | 305 | -40,150,000 | -3,765,800,000 | 19,698,000,000 | 23,463,800,000 |
| ROE | 313 | -23.56% | -466.34% | 275.39% | 741.73% |
| Liabilities / equity | 277 | 0.52 | 0.02 | 73.12 | 73.10 |
Highest reported net margin
| Rank | Company | Net margin | FY | Extra |
|---|---|---|---|---|
| 1 | TBPH - Theravance Biopharma, Inc. | 98.54% | 2025 | |
| 2 | ZVRA - ZEVRA THERAPEUTICS, INC. | 78.17% | 2025 | |
| 3 | TGTX - TG THERAPEUTICS, INC. | 72.56% | 2025 | |
| 4 | INVA - Innoviva, Inc. | 65.92% | 2025 | |
| 5 | PTGX - Protagonist Therapeutics, Inc | 63.34% | 2025 | |
| 6 | XOMA - XOMA Royalty Corp | 60.81% | 2025 | |
| 7 | KRYS - Krystal Biotech, Inc. | 52.64% | 2025 | |
| 8 | CRMD - CorMedix Inc. | 52.31% | 2025 | |
| 9 | LGND - LIGAND PHARMACEUTICALS INC | 46.42% | 2025 | |
| 10 | CYRX - Cryoport, Inc. | 44.44% | 2025 |
Lowest reported net margin
| Rank | Company | Net margin | FY | Extra |
|---|---|---|---|---|
| 1 | IOVA - IOVANCE BIOTHERAPEUTICS, INC. | -148.38% | 2025 | |
| 2 | BBIO - BridgeBio Pharma, Inc. | -145.98% | 2025 | |
| 3 | MRNA - Moderna, Inc. | -145.16% | 2025 | |
| 4 | RCUS - Arcus Biosciences, Inc. | -142.91% | 2025 | |
| 5 | MGTX - MeiraGTx Holdings plc | -140.31% | 2025 | |
| 6 | URGN - UroGen Pharma Ltd. | -139.81% | 2025 | |
| 7 | OCUL - OCULAR THERAPEUTIX, INC | -138.14% | 2025 | |
| 8 | KYMR - Kymera Therapeutics, Inc. | -137.60% | 2025 | |
| 9 | EDIT - Editas Medicine, Inc. | -127.82% | 2025 | |
| 10 | PHAT - Phathom Pharmaceuticals, Inc. | -126.35% | 2025 |
Highest reported operating margin
| Rank | Company | Operating margin | FY | Extra |
|---|---|---|---|---|
| 1 | RPRX - Royalty Pharma plc | 65.58% | 2025 | |
| 2 | PTGX - Protagonist Therapeutics, Inc | 58.20% | 2025 | |
| 3 | VIR - Vir Biotechnology, Inc. | 51.56% | 2025 | |
| 4 | PTCT - PTC THERAPEUTICS, INC. | 50.09% | 2025 | |
| 5 | CRMD - CorMedix Inc. | 48.17% | 2025 | |
| 6 | UTHR - UNITED THERAPEUTICS Corp | 46.89% | 2025 | |
| 7 | CPRX - CATALYST PHARMACEUTICALS, INC. | 43.77% | 2025 | |
| 8 | KRYS - Krystal Biotech, Inc. | 41.45% | 2025 | |
| 9 | NVAX - NOVAVAX INC | 40.30% | 2025 | |
| 10 | INVA - Innoviva, Inc. | 39.81% | 2025 |
Lowest reported operating margin
| Rank | Company | Operating margin | FY | Extra |
|---|---|---|---|---|
| 1 | ADCT - ADC Therapeutics SA | -149.34% | 2025 | |
| 2 | SEPN - Septerna, Inc. | -148.63% | 2025 | |
| 3 | EDIT - Editas Medicine, Inc. | -148.61% | 2025 | |
| 4 | ALEC - Alector, Inc. | -144.19% | 2025 | |
| 5 | XNCR - Xencor Inc | -141.35% | 2025 | |
| 6 | OCUL - OCULAR THERAPEUTIX, INC | -140.96% | 2025 | |
| 7 | KYMR - Kymera Therapeutics, Inc. | -138.03% | 2025 | |
| 8 | DNA - Ginkgo Bioworks Holdings, Inc. | -132.14% | 2025 | |
| 9 | ENTA - ENANTA PHARMACEUTICALS INC | -130.65% | 2025 | |
| 10 | MGTX - MeiraGTx Holdings plc | -130.20% | 2025 |
Largest reported revenue growth
| Rank | Company | Revenue growth | FY | Extra |
|---|---|---|---|---|
| 1 | FDMT - 4D Molecular Therapeutics, Inc. | 230194.59% | 2025 | |
| 2 | VRDN - Viridian Therapeutics, Inc.\DE | 23359.93% | 2025 | |
| 3 | ARWR - ARROWHEAD PHARMACEUTICALS, INC. | 23258.15% | 2025 | |
| 4 | SEPN - Septerna, Inc. | 4174.51% | 2025 | |
| 5 | IDYA - IDEAYA Biosciences, Inc. | 3024.43% | 2025 | |
| 6 | LQDA - Liquidia Corp | 1031.18% | 2025 | |
| 7 | GEVO - Gevo, Inc. | 849.33% | 2025 | |
| 8 | NUVB - Nuvation Bio Inc. | 698.96% | 2025 | |
| 9 | IBRX - ImmunityBio, Inc. | 668.31% | 2025 | |
| 10 | CRNX - Crinetics Pharmaceuticals, Inc. | 640.71% | 2025 |
Largest reported free cash flow
| Rank | Company | Free cash flow | FY | Extra |
|---|---|---|---|---|
| 1 | JNJ - JOHNSON & JOHNSON | 19,698,000,000 | 2025 | |
| 2 | ABBV - AbbVie Inc. | 17,816,000,000 | 2025 | |
| 3 | PG - PROCTER & GAMBLE Co | 14,044,000,000 | 2025 | |
| 4 | BMY - BRISTOL MYERS SQUIBB CO | 12,845,000,000 | 2025 | |
| 5 | MRK - Merck & Co., Inc. | 12,360,000,000 | 2025 | |
| 6 | GILD - GILEAD SCIENCES, INC. | 9,456,000,000 | 2025 | |
| 7 | PFE - PFIZER INC | 9,075,000,000 | 2025 | |
| 8 | AMGN - AMGEN INC | 8,100,000,000 | 2025 | |
| 9 | ABT - ABBOTT LABORATORIES | 7,395,000,000 | 2025 | |
| 10 | LIN - LINDE PLC | 5,089,000,000 | 2025 |
Highest reported ROE
| Rank | Company | ROE | FY | Extra |
|---|---|---|---|---|
| 1 | CHRS - Coherus Oncology, Inc. | 275.39% | ||
| 2 | CLX - CLOROX CO /DE/ | 252.34% | 2025 | |
| 3 | SAFX - XCF Global, Inc. | 196.55% | ||
| 4 | ABBV - AbbVie Inc. | 128.66% | 2025 | |
| 5 | HALO - HALOZYME THERAPEUTICS, INC. | 122.06% | 2025 | |
| 6 | LFCR - LIFECORE BIOMEDICAL, INC. \DE\ | 106.17% | 2025 | |
| 7 | RIGL - RIGEL PHARMACEUTICALS INC | 93.75% | ||
| 8 | AMGN - AMGEN INC | 89.06% | 2025 | |
| 9 | ZTS - Zoetis Inc. | 80.25% | 2025 | |
| 10 | LLY - ELI LILLY & Co | 77.78% | 2025 |
Highest reported liabilities / equity
| Rank | Company | Liabilities / equity | FY | Extra |
|---|---|---|---|---|
| 1 | CL - COLGATE PALMOLIVE CO | 73.12 | 2025 | |
| 2 | NGVT - Ingevity Corp | 54.59 | 2025 | |
| 3 | HALO - HALOZYME THERAPEUTICS, INC. | 50.73 | 2025 | |
| 4 | EOLS - Evolus, Inc. | 41.12 | 2025 | |
| 5 | HUMA - Humacyte, Inc. | 36.43 | 2025 | |
| 6 | CC - Chemours Co | 28.52 | 2025 | |
| 7 | XERS - Xeris Biopharma Holdings, Inc. | 27.02 | 2025 | |
| 8 | LFCR - LIFECORE BIOMEDICAL, INC. \DE\ | 17.68 | 2025 | |
| 9 | INBX - Inhibrx Biosciences, Inc. | 17.33 | 2025 | |
| 10 | HRTX - HERON THERAPEUTICS, INC. /DE/ | 16.85 | 2025 |
Lowest reported liabilities / equity
| Rank | Company | Liabilities / equity | FY | Extra |
|---|---|---|---|---|
| 1 | MNPR - Monopar Therapeutics | 0.02 | ||
| 2 | BNTC - Benitec Biopharma Inc. | 0.02 | ||
| 3 | ORKA - Oruka Therapeutics, Inc. | 0.04 | ||
| 4 | ELVN - Enliven Therapeutics, Inc. | 0.04 | ||
| 5 | VGAS - Verde Clean Fuels, Inc. | 0.04 | ||
| 6 | LBRX - LB PHARMACEUTICALS INC | 0.04 | ||
| 7 | TECX - Tectonic Therapeutic, Inc. | 0.04 | ||
| 8 | UPB - Upstream Bio, Inc. | 0.04 | 2025 | |
| 9 | MBX - MBX Biosciences, Inc. | 0.04 | ||
| 10 | MPLT - MapLight Therapeutics, Inc. | 0.05 |